NNNathalie Niederhoffer

Nathalie Niederhoffer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nathalie Niederhoffer has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Bela Szabo

    Institut für Experimentelle und Klinische Pharmakologie und Toxikologie

    2 shared publications
  • Karin Schmid

    Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Albertstrasse 25, 79104, Freiburg i. Br., Germany

    2 shared publications
  • Klaus Starke

    11Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Universität Freiburg, Albertstrasse 25, D-79104, Freiburg i Br, Germany

    1 shared publication
  • Lutz Hein

    22Institut für Pharmakologie und Toxikologie, Universitat Würzburg, Versbacher Strasse g, D-97078 Würzburg, Germany

    1 shared publication

Latest Publications

  • Open Access

    Modulation of the baroreceptor reflex by α2A‐adrenoceptors: a study in α2A knockout mice

    by Nathalie Niederhoffer, Lutz Hein, Klaus Starke

    Our objective was to determine whether α2A‐adrenoceptors modulate the baroreceptor reflex. The efficacy of the reflex was evaluated by measuring the spontaneous blood pressure and heart rate variability at rest and the heart rate responses to evoked changes in blood pressure. Experiments were carried out in conscious, unrestrained, and anaesthetized α2A‐adrenoceptor‐deficient (α2A‐KO) mice and WT mice. In conscious α2A‐KO mice, the spontaneous blood pressure variability was greater, and the spontaneous heart rate variability was lower than in conscious WT mice. This was also observed in anaesthetized animals. The reflex bradycardia after intravenous injection of phenylephrine was greatly attenuated in conscious α2A‐KO compared to conscious WT mice; the baroreceptor reflex gain (ratio maximal change in heart rate/maximal change in mean arterial pressure) was decreased by 40%. Similar results were obtained when reflex bradycardia was elicited by intra‐arterial volume loading of conscious WT and α2A‐KO mice. The baroreceptor reflex gain upon volume loading was also low in anaesthetized α2A‐KO mice. The reflex tachycardia evoked by intravenous sodium nitroprusside injection was also significantly less in α2A‐KO mice as compared to WT, conscious as well as anaesthetized; the baroreceptor reflex gains were decreased by 50 and 65%, respectively. Direct stimulation of cardiac β‐adrenoceptors by the agonist isoprenaline produced similar cardioacceleration in α2A‐KO and WT animals. Our results show that the baroreceptor reflex function is impaired in mice lacking α2A‐adrenoceptors. We conclude that central α2A‐adrenoceptors facilitate the reflex response to both loading and unloading of the arterial baroreceptors. British Journal of Pharmacology (2004) 141, 851–859. doi:10.1038/sj.bjp.0705636


  • Analysis of the respiratory effects of cannabinoids in rats

    by Karin Schmid, Nathalie Niederhoffer, Bela Szabo

    The objective of the present study was to evaluate the respiratory effects of cannabinoids and their influence on cardiovascular homeostasis. In spontaneously breathing urethane-anaesthetised rats, intravenous injection of the two synthetic cannabinoid receptor agonists WIN55212-2 and CP55940 strongly and dose-dependently lowered mean arterial pressure, heart rate and the plasma noradrenaline concentration. The cardiovascular depressive effects were associated with a large decrease in respiratory rate, hypoxia, hypercapnia and blood acidosis. All depressor effects of WIN55212-2 were abolished by the selective CB1 cannabinoid receptor antagonist SR141716A. The bradycardia elicited by WIN55212-2 was inhibited by the muscarinic acetylcholine receptor antagonist methylatropine. The natural agonist Δ9-tetrahydrocannabinol also elicited cardiovascular and respiratory depression. In contrast, WIN55212-3, an enantiomer of WIN55212-2 lacking affinity for cannabinoid receptors, had no effect. The cannabinoid-evoked decreases in blood pressure and heart rate were much more pronounced in spontaneously breathing than in artificially ventilated urethane-anaesthetised rats. In contrast, the plasma noradrenaline concentration was lowered equally in both preparations. Our results show that activation of CB1 cannabinoid receptors not only induces cardiovascular depression, but also markedly impairs ventilation. The second major finding of the present study is that the respiratory depression evoked by cannabinoids largely amplifies the cardiovascular depression.


  • The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression

    by Nathalie Niederhoffer, Karin Schmid, Bela Szabo

    Our objective was to identify the sites of interaction of cannabinoids with cardiovascular sympathetic regulation in the rat. Effects on sympathetic tone were first determined in anaesthetised animals following i.v. administration of the drugs. Central effects were evaluated in anaesthetised rats receiving microinjections of cannabinoids into brain stem nuclei. Peripheral effects were identified in pithed rats with electrically stimulated sympathetic outflow. In anaesthetised and artificially ventilated rats, i.v. injection of the cannabinoid agonists WIN55212-2 and CP55940 decreased mean arterial pressure, heart rate and the plasma noradrenaline concentration. These effects were antagonized by the CB1 cannabinoid receptor antagonist SR141716A. The bradycardia was abolished by the muscarinic acetylcholine receptor antagonist methylatropine. The decreases in mean arterial pressure and heart rate caused by cannabinoids in ventilated rats were much less pronounced than in spontaneously breathing rats. Microinjection of WIN55212-2 into the nucleus tractus solitarii had no effect. Microinjected into the rostral ventrolateral medulla oblongata, WIN55212-2 lowered mean arterial pressure slightly without changing other parameters. In pithed rats, WIN55212-2 inhibited the increases in mean arterial pressure, heart rate and the plasma noradrenaline concentration evoked by electrical stimulation of the sympathetic outflow. Our results show that activation of CB1 cannabinoid receptors induces sympathoinhibition and enhancement of cardiac vagal tone, leading to hypotension and bradycardia. Presynaptic inhibition of noradrenaline release from terminals of postganglionic sympathetic neurons is the major component of the sympathoinhibition, but an effect in the rostral ventrolateral medulla oblongata may also contribute. The cannabinoid-evoked cardiovascular depression depends strongly on the respiratory state of the animals.